Funding

Remedium Bio

United States · Biotech · Enterprise software

Develops durable protein therapeutics via gene therapy for chronic diseases

Visit remedium-bio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A$10MEli Lilly and Company — Role not disclosedHKX Capital — Role not disclosedLifespan Vision Ventures — Role not disclosed

Investors

Eli Lilly and CompanySeries AHKX CapitalSeries ALifespan Vision VenturesSeries A

Coverage

Aug 10, 2026Remedium Bio · Series A

Similar companies

Knowledge WorkTokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.¥4.8B · Series C debt second close
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcesremedium-bio.com ↗